Amylyx Pharmaceuticals (AMLX) Change in Receivables (2022 - 2025)

Amylyx Pharmaceuticals' Change in Receivables history runs 4 years deep, the most recent figure standing at -$44000.0 for Q4 2025.

• In Q4 2025, Change in Receivables rose 96.57% year-over-year to -$44000.0; the TTM figure through Dec 2025 stood at -$359000.0 (up 99.09% YoY), while the FY2025 annual figure was -$359000.0, up 99.09% from the prior year.
• Change in Receivables was -$44000.0 for Q4 2025 at Amylyx Pharmaceuticals, down from $30000.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $15.9 million in Q2 2023 to a low of -$19.7 million in Q1 2024.
• Historically, Change in Receivables has averaged -$3692.3 across 4 years, with a median of -$147000.0 in 2025.
• The sharpest annual moves came in 2024 and 2025: Change in Receivables tumbled 975.86% in 2024, then jumped 101.27% in 2025.
• A 4-year view of Change in Receivables shows it stood at $15.2 million in 2022, then decreased by 29.48% to $10.7 million in 2023, then tumbled by 111.99% to -$1.3 million in 2024, then surged by 96.57% to -$44000.0 in 2025.
• The last three Change in Receivables figures came in at -$44000.0 (Q4 2025), $30000.0 (Q3 2025), and -$198000.0 (Q2 2025), per Business Quant data.